Janssen Inc.
26
5
6
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
2 terminated/withdrawn out of 26 trials
89.5%
+2.9% vs industry average
15%
4 trials in Phase 3/4
12%
2 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Role: collaborator
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Role: collaborator
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Role: collaborator
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
Role: collaborator
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Role: collaborator
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
Role: collaborator
Plan Development for Giving Teclistamab in the Outpatient Setting
Role: collaborator
Biologic Treatment Registry Across Canada
Role: lead
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
Role: collaborator
Golimumab for Adherence in Rheumatoid Arthritis
Role: lead
A Study of Participants With Advanced Prostate Cancer in Canada
Role: lead
Prucalopride Versus Placebo in Gastroparesis
Role: collaborator
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Role: lead
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Role: collaborator
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
Role: collaborator
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
Role: lead
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
Role: lead
Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule
Role: collaborator
Observational Study of Golimumab Intravenous Infusion
Role: lead
Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting
Role: collaborator